NASDAQ, AMGN - Amgen Inc

Amgen Inc. (including its subsidiaries, referred to as ?Amgen,? ?the Company,?  ?we,? ?our? and ?us?) was incorporated in 1980 and is a global biotechnology  company that discovers, develops, manufactures and markets human therapeutics  based on advances in cellular and molecular biology. We operate in one business  segment ? human therapeutics.  We market human therapeutic products in the areas of supportive cancer care,  nephrology, inflammation and oncology. Our principal products include Aranesp?  (darbepoetin alfa), EPOGEN ? (Epoetin alfa), Neulasta? (pegfilgrastim),  NEUPOGEN? (Filgrastim) and Enbrel ? (etanercept). Aranesp? and EPOGEN? stimulate  the production of red blood cells to treat anemia and belong to a class of drugs  referred to as erythropoiesis-stimulating agents (?ESAs?). Aranesp? is used for  the treatment of anemia both in supportive cancer care and in nephrology.  EPOGEN? is used to treat anemia associated with chronic renal failure (?CRF?).  ...

Sector:	Health Care
Industry:	Biotechnology: Biological Products (No Diagnostic Substances)
P/E Ratio:	27.1621
PEG Ratio:	3.29
EPS:	10.98
DivYield:	2.61
PtB:	25.8351
PtS:	5.59
EBITDA:	12.36B
Shares:	537.71M
Market Cap:	154.983B
52wk range:	253.30 - 339.17

216.73.216.229
United States